ATE550023T1 - Stabile feste zubereitung mit 4,5- epoxymorphinanderivat - Google Patents

Stabile feste zubereitung mit 4,5- epoxymorphinanderivat

Info

Publication number
ATE550023T1
ATE550023T1 AT08752145T AT08752145T ATE550023T1 AT E550023 T1 ATE550023 T1 AT E550023T1 AT 08752145 T AT08752145 T AT 08752145T AT 08752145 T AT08752145 T AT 08752145T AT E550023 T1 ATE550023 T1 AT E550023T1
Authority
AT
Austria
Prior art keywords
solid preparation
stable solid
derivative
epoxymorphinand
effective ingredient
Prior art date
Application number
AT08752145T
Other languages
English (en)
Inventor
Suguru Takaki
Kotoe Ohta
Yasuhide Horiuchi
Masato Kobayashi
Junko Kawasaki
Eijiro Horisawa
Original Assignee
Toray Industries
Maruho Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries, Maruho Kk filed Critical Toray Industries
Application granted granted Critical
Publication of ATE550023T1 publication Critical patent/ATE550023T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epoxy Compounds (AREA)
  • Epoxy Resins (AREA)
AT08752145T 2007-04-26 2008-04-25 Stabile feste zubereitung mit 4,5- epoxymorphinanderivat ATE550023T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007116721 2007-04-26
PCT/JP2008/058111 WO2008133330A1 (ja) 2007-04-26 2008-04-25 4,5-エポキシモルヒナン誘導体を含有する安定な固形製剤

Publications (1)

Publication Number Publication Date
ATE550023T1 true ATE550023T1 (de) 2012-04-15

Family

ID=39925776

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08752145T ATE550023T1 (de) 2007-04-26 2008-04-25 Stabile feste zubereitung mit 4,5- epoxymorphinanderivat

Country Status (14)

Country Link
US (1) US8420662B2 (de)
EP (1) EP2151241B1 (de)
JP (2) JP5099127B2 (de)
KR (1) KR101491656B1 (de)
CN (1) CN101686976B (de)
AT (1) ATE550023T1 (de)
AU (1) AU2008244936B2 (de)
CA (1) CA2685131C (de)
DK (1) DK2151241T3 (de)
ES (1) ES2381056T3 (de)
MX (1) MX2009011554A (de)
PL (1) PL2151241T3 (de)
PT (1) PT2151241E (de)
WO (1) WO2008133330A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI455733B (zh) 2009-03-30 2014-10-11 Toray Industries 口腔內崩壞性被覆錠劑
BR112013009505B1 (pt) * 2010-10-19 2022-06-21 Memorial Sloan-Kettering Cancer Center Composto, composição farmacêutica, métodos para ensaio quanto a um receptor, e, usos de um composto
JP2013087170A (ja) * 2011-10-17 2013-05-13 Nippon Soda Co Ltd ヒドロキシプロピルセルロース微粒子
JP5818219B2 (ja) 2012-05-14 2015-11-18 塩野義製薬株式会社 6,7−不飽和−7−カルバモイルモルヒナン誘導体含有製剤
GB201318394D0 (en) * 2013-10-17 2013-12-04 Univ Edinburgh Composition
EP4212532A3 (de) 2015-04-30 2023-09-27 Memorial Sloan Kettering Cancer Center Mitragynin-analoga und verwendungen davon
CN105461727A (zh) * 2015-12-01 2016-04-06 吕涛 一种纳呋拉啡的精制方法
CN109562109A (zh) 2016-07-29 2019-04-02 东丽株式会社 光稳定性提高的固体制剂
EP3603643B1 (de) 2017-03-31 2021-09-15 Toray Industries, Inc. Tablettierte medizinische zusammensetzung, nalfurafin umfassend
CA3091752A1 (en) 2018-03-08 2019-09-12 Victoria Link Ltd Treatment of demyelinating diseases
WO2020205735A1 (en) 2019-03-29 2020-10-08 Humanwell Pharmaceutical US Novel morphinans useful for treating medical disorders
MX2023014819A (es) 2021-06-14 2024-03-21 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cancer.
EP4212149A1 (de) * 2022-01-18 2023-07-19 Rijksuniversiteit Groningen Orale dosierungsformen von säurelabilen salzen und verfahren und verwendung davon

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8820327D0 (en) 1988-08-26 1988-09-28 May & Baker Ltd New compositions of matter
JP2525552B2 (ja) 1992-01-23 1996-08-21 東レ株式会社 モルヒナン誘導体および医薬用途
CN1535687A (zh) 1996-11-25 2004-10-13 ������������ʽ���� 止痒药物
WO1998035679A1 (de) 1997-02-14 1998-08-20 Gödecke Aktiengesellschaft Stabilisierung von naloxonhydrochlorid
JP4939680B2 (ja) 1997-05-27 2012-05-30 武田薬品工業株式会社 固形製剤
TW580397B (en) * 1997-05-27 2004-03-21 Takeda Chemical Industries Ltd Solid preparation
CA2265767C (en) 1997-07-11 2007-12-04 Nobuyuki Hanamura Stable pharmaceutical composition including 4,5-epoxy-morphinan derivative
US6524568B2 (en) * 1998-06-22 2003-02-25 Cytomedix, Inc. Enriched platelet wound healant
JP3698652B2 (ja) 2000-03-17 2005-09-21 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース含有固形製剤及びその製造方法
DE60110666T2 (de) 2000-03-17 2006-02-02 Shin-Etsu Chemical Co., Ltd. Feste Zubereitung enthaltend niedersubstituierte Hydroxypropylcellulose und Herstellungsverfahren
AU2001248751A1 (en) 2000-04-12 2001-10-23 Banyu Pharmaceutical Co. Ltd. Compositions disintegrating in oral cavity and preparations disintegrating in oral cavity
JP3595765B2 (ja) * 2000-09-27 2004-12-02 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロースを含む乾式直打用基剤
WO2002070013A1 (en) 2001-03-06 2002-09-12 Kyowa Hakko Kogyo Co., Ltd. Utilization of spray-dried powder containing sugar alcohol
AU2003220290B2 (en) 2002-03-14 2007-06-14 Euro-Celtique S.A. Naltrexone hydrochloride compositions
EP1552851A1 (de) 2002-06-10 2005-07-13 Dainippon Pharmaceutical Co., Ltd. Schnell zerfallende tablette und verfahren zu ihrer herstellung
PL2368554T3 (pl) 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson

Also Published As

Publication number Publication date
EP2151241A1 (de) 2010-02-10
US20100120815A1 (en) 2010-05-13
CA2685131C (en) 2015-05-19
AU2008244936B2 (en) 2013-02-21
WO2008133330A1 (ja) 2008-11-06
MX2009011554A (es) 2010-01-25
KR20100015582A (ko) 2010-02-12
JP2012180382A (ja) 2012-09-20
JPWO2008133330A1 (ja) 2010-07-29
KR101491656B1 (ko) 2015-02-09
PT2151241E (pt) 2012-05-07
US8420662B2 (en) 2013-04-16
CA2685131A1 (en) 2008-11-06
EP2151241B1 (de) 2012-03-21
AU2008244936A1 (en) 2008-11-06
JP5578199B2 (ja) 2014-08-27
DK2151241T3 (da) 2012-04-23
PL2151241T3 (pl) 2012-08-31
CN101686976B (zh) 2013-04-24
CN101686976A (zh) 2010-03-31
JP5099127B2 (ja) 2012-12-12
EP2151241A4 (de) 2010-06-02
ES2381056T3 (es) 2012-05-22

Similar Documents

Publication Publication Date Title
DK2151241T3 (da) Stabilt fast præparat, omfattende 4,5-epoxymorphinanderivat
MA32604B1 (fr) Composes organiques
EA200900044A1 (ru) Замещенные производные 1,3-дифенилпропана, получение и их применение
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
EA201070698A1 (ru) Твердые формы 3-(6-(1-(2,2-дифторбензо[d][1,3]-диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
UY28797A1 (es) 5,6-dialquil-7-amino-triazolopirimidinas, procedimientos para su preparación y el uso de las mismas para combatir hongos nocivos, así como productos que las contienen.
MX2011011175A (es) Coposiciones herbicidas de alta concentracion de las sales de glifosato y de 2,4-d.
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
JP2015514120A5 (de)
FI3817751T3 (fi) Vedettömän natriumtiosulfaatin formulaatioita
EA201300715A1 (ru) Бульонный кубик
BRPI0922701A8 (pt) Método para intensificar atividade viral mediada por interferon em um animal de companhia
GT201400027A (es) Acuosa suspensión concentrada que comprende un ácido sal de dodecilguanidina
MA30554B1 (fr) Malates et formes polymorphes de l'acide ( 3s,5s)-7-[3-amino-5-methyl-piperidinyl ]-1-cyclopropyl-1,4-dihydro-8- methoxy-4-oxo-3-quinoleine-carboxylique
CO6351744A2 (es) Sales de n-[6-(cis-2,6-dimetil-morfolin-4-il)-piridini-3-il]-2-metil-4´-(trifluoro-metoxi)-[1,1´-bifenil]-3-carboxamida
DK2170415T3 (da) Antimikrobielt præparat
MA32498B1 (fr) Compositions pharmaceutiques de rosuvastatine calcium
CY1116266T1 (el) Σταθερα αλατα της s-αδενοσυλμεθειονινης και μεθοδος παρασκευης τους
PT2146683E (pt) Utilização de um extrato aquoso de sementes de uva em associação com pelo menos um sal de flúor contra a formação ou acumulação de biofilme dentário e composições compreendendo essa associação
BR112012014564A2 (pt) "método de combate e controle de pragas"
IL194094A0 (en) Stable pharmacuetical compositions of 2-aza-bicyclol[3.3.0]-octane-3-carboxylic acid derivatives
DE602004029459D1 (de) Verbessertes reinigungsmittel
MX2009012841A (es) Nuevos derivados del acido 3-fenil propanoico que son activadores de los receptores del tipo del receptor activado por el proliferador de peroxisoma, su metodo de preparacion y su uso en composiciones cosmeticas o farmaceuticas.
EP1961751A4 (de) Säureadditionssalz eines optisch aktiven dihydropyridinderivat